Amato R
Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA.
Oncology (Williston Park). 2000 Dec;14(12 Suppl 13):33-6.
A pilot study was performed at The University of Texas M. D. Anderson Cancer Center to determine the feasibility of using thalidomide in a population of renal-cell carcinoma patients who had progressive disease despite chemotherapy and immunotherapy. Metastatic renal-cell carcinoma patients with adequate oral function were entered onto a study after signing an internal review board-approved informed consent. There were no exclusion criteria for prior therapy. Nineteen previously treated patients and one untreated patient with progressive renal-cell carcinoma received oral thalidomide as a single agent. The starting dose was 200 mg and the dose was increased by 100 to 200 mg every week until it reached 1,200 mg/d. Response was assessed on the basis of a radiographic reduction of the metastatic sites involved. A case report describing one of the patients involved in the pilot trial is included.
德克萨斯大学MD安德森癌症中心开展了一项初步研究，以确定在尽管接受了化疗和免疫治疗但病情仍进展的肾细胞癌患者群体中使用沙利度胺的可行性。具有足够口腔功能的转移性肾细胞癌患者在签署内部审查委员会批准的知情同意书后进入研究。既往治疗没有排除标准。19例既往接受过治疗且病情进展的肾细胞癌患者和1例未经治疗的患者接受了口服沙利度胺单药治疗。起始剂量为200mg，每周剂量增加100至200mg，直至达到1200mg/d。根据所累及转移部位的影像学缩小情况评估疗效。本文还纳入了一份描述参与该初步试验的其中一名患者的病例报告。
